Ionpath is a venture-backed platform company that is transforming cancer diagnosis with Multiplexed Ion Beam Imaging (MIBI): a next generation tissue analyzer (Nature Medicine 2014, PMID 24584119). T...
Ionpath is a venture-backed platform company that is transforming cancer diagnosis with Multiplexed Ion Beam Imaging (MIBI): a next generation tissue analyzer (Nature Medicine 2014, PMID 24584119). The MIBI Tissue Analyzer is a proprietary, mass spectrometry based microscopy platform that permits simultaneous, quantitative analysis of 135 biomolecules on a single tissue section. New MIBI instrumentation and methods developed by Ionpath now allow this imaging to occur on a scale that exceeds the sensitivity, throughput, and resolution of conventional clinical light microscopy.